CD4 and neoplasm: While ONP-302 treatment slowed B16.F10 tumor growth as compared to control treated mice, ONP-302 treatment resulted in increased percentages of PD-1+ CD4+ T cells, PD-1+ CD8+ T cells, PD-1+ NK cells, and PD-L1+ myeloid cells.